Abstract:Objective To observe the efficacy and safety of insulin aspart in intensive insulin therapy of hyperglycemia in medical critically ill patients.Methods A total of 186 medical critically ill patients with fasting blood glucose (10.8±2.3) mmol/L were divided into multiple daily insulin (MDI)group (n = 90) and continous subcutaneous insulin infusion (CSⅡ) group (n = 96),both groups were divided into insulin aspart subgroup and human regular insulin subgroup randomly.Bonus dosage was offered by insulin aspart or human regular insulin in MDI group,base dosage was offered by Glagine.Bonus and base dosage were offered by insulin aspart or human regular insuline in CSⅡ group.The dosage of insulin was adjusted according to multi-points blood glucose levels.The course of intensive insulin therapy was 7 days with blood glucose levels 4.4 ～ 8.3 mmol/L,and it was changed to regular insulin therapy after 7 days with blood glucose levels 4.4～11.1 mmol/L.Average blood glucose level,blood glucose standard deviation,the equation of the highest and the lowest blood glucose level in one day,percentage of total hypoglycemia and serious hypoglycemia,average insulin dosage,decline of blood CRP level and APACHE Ⅱ during 7 days,and mortality during twenty eight days were observed.Results (1) There were no statistical significance in difference on lab items before intensive insulin therapy in both subgroups.(2) Compared to human regular insulin subgroup,insulin aspart subgroup was lower in average blood glucose level.MDI group:(6.17±1.32) mmol/L vs (7.6±1.6) mmol/L;CSⅡ group:(6.0±1.2) mmol/L vs (7.4±2.5) mmol/L,P ＜0.05 respectively.Standard deviation MDI group:(1.54±0.27) mmol/L vs (1.92±0.38) mmol/L;CSⅡ group:(1.24 ±0.27) mmol/L vs (1.83±0.45) mmol/L,respectively (P＜0.05).The equation MDI group:(3.0±0.5)mmol/Lvs (3.9±1.1) mmol/L;CSII group:(3.1±0.6) mmoL/Lvs (3.9±1.0)mmol/L,respectively(P＜0.05).CSⅡ group were lower in seventh day of intensive insulin therapy;average insulin dosage was less (MDI group:(38±3)U/d vs (42±4)U/d;CSⅡ group:(37±4)U/d vs (40±6)U/d,P ＜0.05 respectively),percentage of total hypoglycemia (MDI group:17.4% vs 27.3%;CSⅡ group:8.0% vs 17.4%,P＜0.05 respectively) and serious hypoglycemia (MDI group:4.3% vs 15.9%;CSⅡ group:2.0% vs 6.5%,P ＜0.05 respectively) was lower during seven days,decline of blood CRP level during seven days was more obvious (MDI group:(44.8±1.6) mg/L vs (27.8±1.2) mg/L;CSⅡ group:(57.7±2.4) mg/L vs (36.7 ±1.2) mg/L,P＜0.05 respectively),decline of APACHE Ⅱ during seven days was more obvious (MDI group:(7.5±2.1) score vs (4.3±1.1) score;CSⅡ group:(8.4±1.3) score vs (6.1±1.5) score,P＜0.05 respectively);mortality was not different in statistical during twenty eight days (MDI group:13.0% vs 13.6%;CSⅡ group:6.0% vs 6.5%,P＞0.05 respectively).Conclusion Insulin aspart can better control average blood glucose and its variability,lower the percentage of hypoglycemia,save insulin dosage and relieve inflammation than human regular insulin in treating hyperglycemia of medical critically ill patients.

Insulin Aspart is Better Than Human Regular Insulin in Intensive Therapy for Critical Care Patients

Clinical observation and nursing care on patients with type 2 diabetes applied as continuous subcutaneous insulin infusion

A Comparison of Efficacy and Safety in the Treatment of Hyperglycemia with Continuous Subcutaneous Insulin with Insulin Pump or Multiple Insulin Injections Daily in Critical Elderly Patients

Comparison between the effects of insulin Aspart and Novolin R via continuous subcutaneous insulin infusion pump on hyperglycemia in elderly patients with type 2 diabetes

Impact of insulin therapy to control blood glucose on different levels on criticaly ill patients

[The Comparison of Insulin Aspart and Human Soluble Insulin Used in Insulin Pump Therapy in Newly Diagnosed Type 2 Diabetic Patients].

Clinical Study of Pumps of Insulin Aspart in Treatment of New-Diagnosed Diabetic Patients

Comparison of efficacy and safety of insulin glulisine and insulin aspart in treatment of islet beta cell dysfunction in type 2 diabetes patients

Meta-analysis of insulin aspart versus regular human insulin in diabetes treatment in China

Impact of Intensive Insulin Therapy on Surgical Critically Ill Patients

Intensive Insulin Therapy on Stress Hyperglycemia in Critical Ill Patients

A 2-Way Cross-Over, Open-Labeled Trial to Compare Efficacy and Safety of Insulin Aspart and Novolin R Delivered with CSII in 21 Chinese Diabetic Patients

Comparison of the efficacy between short term intensive therapy by insulin pump and multiple subcutaneous insulin injections

[Postprandial Glycemic Control Using Insulin Aspart with NPH in Inadequately Controlled Diabetics].

Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus

Comparison of therapeutic efficacy between Aspart and regular human insulin delivered by insulin pump

Improved Safety and Effectiveness of Biphasic Insulin Aspart 30 in Type 2 Diabetic Patients Inadequately Controlled on Human Insulin: Chinese Subgroup Analysis from an International, Multicenter A1chieve Observational Study

Safety and Efficacy of Insulin Aspart Versus Regular Human Insulin in Pregnant Women with Abnormal Glucose Metabolism

Observation of curative effect on Insulin Aspartate in the treatment of newly diagnosed type 2 diabetes mellitus

Comparison of the Therapeutic Efficacy Between Human Insulin 30R Combined with Acarbose and Insulin Aspart 30 on the Postprandial Blood Glucose in Patients with Type 2 Diabetes

Application of intensive insulin therapy in critical illnesses